Hangzhou Tigermed Consulting Co., Ltd. (03347.HK) Latest Company News

Oct 29, 2026, 10:14 UTC
Tigermed reported third-quarter 2026 revenue of RMB2.083 billion, up 17.38% year on year, and net profit of RMB141 million, down 77.85%.
Source:
- aastocks.com
Oct 29, 2026, 09:41 UTC
Hangzhou Tigermed Consulting reported a net loss attributable to shareholders of RMB272 million for the nine months ended September 30, 2026, compared with net profit of RMB1.02 billion a year earlier, and a loss per share of RMB0.32.
Source:
- aastocks.com
- aastocks.com
Oct 22, 2026, 00:08 UTC
Tigermed's subsidiary Frontage Holdings Corp. temporarily suspended trading in its shares pending an announcement containing inside information.
Source:
Oct 16, 2026, 11:10 UTC
Zhejiang Securities Regulatory Bureau warned Ye Xiaoping and Cao Xiaochun and fined each 500,000 yuan for failing to promptly disclose a simplified report on changes in shareholdings.
Source:
- finance.sina.cn
Sep 21, 2026, 02:12 UTC
Hong Kong-listed biopharmaceutical stocks rallied broadly on September 21, with Shanghai Henlius Biotech up over 10%, Junshi Biosciences and Akeso up over 8%, Keymed Biosciences and InnoCare Pharma up over 7%, and RemeGen, GenScript Biotech, WuXi Biologics and Kelun-Biotech up over 6%.
Source:
- aastocks.com
Sep 11, 2026, 10:15 UTC
China's Zhejiang Securities Regulatory Bureau issued warning letters and a prior notice of administrative penalty to Tigermed's actual controllers Ye Xiaoping and Cao Xiaochun over late disclosure of shareholding changes.
Source:
Aug 28, 2026, 08:53 UTC
Tigermed reported a net loss of 413 million yuan attributable to shareholders for the first half of 2026, swinging from a profit of 383 million yuan a year earlier, while revenue grew 14.06% year-on-year to 3.708 billion yuan.
Source:

03347.HK

Tigermed reported third-quarter 2026 revenue of RMB2.083 billion, up 17.38% year on year, and net profit of RMB141 million, down 77.85%.

Hangzhou Tigermed Consulting reported a net loss attributable to shareholders of RMB272 million for the nine months ended September 30, 2026, compared with net profit of RMB1.02 billion a year earlier, and a loss per share of RMB0.32.

Tigermed's subsidiary Frontage Holdings Corp. temporarily suspended trading in its shares pending an announcement containing inside information.

Zhejiang Securities Regulatory Bureau warned Ye Xiaoping and Cao Xiaochun and fined each 500,000 yuan for failing to promptly disclose a simplified report on changes in shareholdings.

Hong Kong-listed biopharmaceutical stocks rallied broadly on September 21, with Shanghai Henlius Biotech up over 10%, Junshi Biosciences and Akeso up over 8%, Keymed Biosciences and InnoCare Pharma up over 7%, and RemeGen, GenScript Biotech, WuXi Biologics and Kelun-Biotech up over 6%.

China's Zhejiang Securities Regulatory Bureau issued warning letters and a prior notice of administrative penalty to Tigermed's actual controllers Ye Xiaoping and Cao Xiaochun over late disclosure of shareholding changes.

Tigermed reported a net loss of 413 million yuan attributable to shareholders for the first half of 2026, swinging from a profit of 383 million yuan a year earlier, while revenue grew 14.06% year-on-year to 3.708 billion yuan.